
It is not only Coloplast’s top and bottom lines that have taken leaps in the first quarter of the skewed financial year 2021/2022.
The medtech company’s production costs also moved up a notch compared to the same period the year before, as evident in Coloplast’s financial results that were publicized on Tuesday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app